This is the
talk page for discussing improvements to the
Eicosanoyl-5-hydroxytryptamide redirect. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google ( books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This redirect does not require a rating on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||
|
The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
The article has a great list of references but further reading material is not supplied. For example links to the Princeton page on the EHT discovery, a supplement that contains EHT, and other content not cited in the article but that might expand a users understanding of EHT. Should we add links to this content? — Preceding unsigned comment added by Etownunder ( talk • contribs) 16:27, 5 January 2015 (UTC)
There is only one Article from a peer review source that addresses EHT directly. In the scientific community this is has promise but not well researched. There will need to be much more research before it is truly accepted. Here is the abstract from the site. Neurobiol Aging. 2014 Dec;35(12):2701-12. doi: 10.1016/j.neurobiolaging.2014.06.012. Epub 2014 Jun 17.
Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.
Basurto-Islas G1, Blanchard J1, Tung YC1, Fernandez JR2, Voronkov M2, Stock M2, Zhang S3, Stock JB4, Iqbal K5.
Abstract
A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2(PP2A), or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.
This is the
talk page for discussing improvements to the
Eicosanoyl-5-hydroxytryptamide redirect. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google ( books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This redirect does not require a rating on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||
|
The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
The article has a great list of references but further reading material is not supplied. For example links to the Princeton page on the EHT discovery, a supplement that contains EHT, and other content not cited in the article but that might expand a users understanding of EHT. Should we add links to this content? — Preceding unsigned comment added by Etownunder ( talk • contribs) 16:27, 5 January 2015 (UTC)
There is only one Article from a peer review source that addresses EHT directly. In the scientific community this is has promise but not well researched. There will need to be much more research before it is truly accepted. Here is the abstract from the site. Neurobiol Aging. 2014 Dec;35(12):2701-12. doi: 10.1016/j.neurobiolaging.2014.06.012. Epub 2014 Jun 17.
Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.
Basurto-Islas G1, Blanchard J1, Tung YC1, Fernandez JR2, Voronkov M2, Stock M2, Zhang S3, Stock JB4, Iqbal K5.
Abstract
A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2(PP2A), or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.